Immunotherapy drugs called immune checkpoint inhibitors have proven to be very effective in patients with melanoma. Findings from this new study suggest, however, that patients with desmoplastic melanoma may be even more likely to have their tumors shrink after treatment with checkpoint inhibitors than patients with the more common form of melanoma.
In the study, a research team led by investigators from the UCLA Jonsson Comprehensive Cancer Center analyzed data from a small group of patients with advanced desmoplastic melanoma who had been treated with checkpoint inhibitors. The trial includes a broader spectrum of patients than those included in the Nature study, including patients with earlier-stage disease, in the hope that the treatment might spare some patients from having to undergo what can be highly disfiguring surgery to remove their tumors.
The approvals were based on large clinical trials showing that the drugs can shrink tumors in many patients and, in a smaller percentage of patients, keep the disease from returning for extended periods. Several factors make melanoma particularly amenable to therapies that work by revving up the immune system. One of the most important factors appears to be that melanoma cells tend to have a large number of genetic mutations. It results primarily from damage to the skin caused by excessive exposure to DNA-damaging ultraviolet light which is why it forms most often on the head and shoulders.
Desmoplastic melanoma tumors are typically surrounded by thick layers of fibrous tissue and snake along and around nerves. Studies have shown that tumor cells in patients with desmoplastic melanoma typically have a very large number of genetic mutations. With that fact in mind, the UCLA-led team gathered data from patients with desmoplastic melanoma who were treated with checkpoint inhibitors to see if that high mutational burden translated into good outcomes.
For the study, Dr. Ribas and his colleagues reviewed data from more than 1, patients with advanced melanoma who were treated at 10 high-volume cancer centers between and All of the patients had been treated with immune checkpoint inhibitors that target the proteins PD-1 or PD-L1.
From that review, they identified 60 patients with desmoplastic melanoma, none of whom had undergone surgery because their disease was too widespread. More than half of these patients had disease characteristics that are associated with a particularly poor prognosis, the research team reported. Several patients who experienced only some reduction in the size of their tumors a partial response were eventually able to undergo surgery to have them removed. Two of these patients were still alive 5 years later, and one was alive nearly 2 years later, without any recurrence of their cancer.
An Exclusive Club
Hu-Lieskovan acknowledged. Nevertheless, she added, the findings still offer a particularly promising outlook. The NCI-funded clinical trial is enrolling patients with advanced and earlier-stage desmoplastic melanoma.
- Rick Franzo.
- Lots of Mutations: A Therapeutic Opportunity?.
- Hot-Shot Tycoon, Indecent Proposal (Mills & Boon Modern Heat).
- Questions For Your Doctor: Ocular Melanoma Follow-Up Care.
- Rare Cancer, Many Responses.
- how horseshoes saved my life a tale of two brain tumors Manual.
- Introduction To Magical Creatures: Mermaids, Unicorns, & Fairies.
So, for patients with advanced desmoplastic melanoma, the trial will do two things, explained Elad Sharon, M. And, second, based on studies built into the trial, it could provide other important insights. Kendra said. Patients enrolled in the trial with earlier-stage disease are candidates for, but have yet to undergo, surgery. These patients, Dr. Sharon said, are receiving pembrolizumab prior to surgery neoadjuvant therapy.
Sharon said. Complete responses, or even very good partial responses, could spare many patients from having to undergo surgery at all or reduce the extent of their surgery, Dr. Kendra explained. Importantly, she added, patients in the trial who are receiving pembrolizumab prior to surgery are undergoing only three cycles of treatment, potentially sparing them from additional side effects.
Menu Contact Dictionary Search. What Is Cancer? Cancer Statistics. Cancer Disparities. Cancer Causes and Prevention. Risk Factors. Cancer Prevention Overview. Cancer Screening Overview. Screening Tests. Diagnosis and Staging. Questions to Ask about Your Diagnosis.
Sophie’s Story: Cannakids, Helping Children Heal
Types of Cancer Treatment. Side Effects of Cancer Treatment. Clinical Trials Information. A to Z List of Cancer Drugs.
About Us - The Growth Coach Poconos
Questions to Ask about Your Treatment. Feelings and Cancer. Adjusting to Cancer. Support for Caregivers. Questions to Ask About Cancer. Choices for Care. Talking about Your Advanced Cancer. Planning for Advanced Cancer. Advanced Cancer and Caregivers. Questions to Ask about Advanced Cancer. Finding Health Care Services. Advance Directives.
Using Trusted Resources. Adolescents and Young Adults with Cancer. Reports, Research, and Literature. Late Effects of Childhood Cancer Treatment. Pediatric Supportive Care. Unusual Cancers of Childhood Treatment. Childhood Cancer Genomics. This dad's touching gesture of getting a tattoo to match his son's cancer scar is winning the internet "If people want to stare at you, then they can stare at both of us.
Josh Marshall sporting his new tattoo, with his son Gabriel. This dad is winning hearts all around the world. Get real-time alerts and all the news on your phone with the all-new India Today app. Download from. Post your comment. Do You Like This Story? Now share the story Too bad.
Related How Horseshoes Saved My Life: A Tale of Two Brain Tumors
Copyright 2019 - All Right Reserved